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GSK-3 is a multifunctional kinase that is located in the cytosol, nucleus, and mitochondria
of all cell types, and it is involved in the pathogenesis of a variety of diseases. In cancer,
GSK-3 modulates the response of the cell death machinery to stress stimuli, including
chemotherapeutics. Mitochondria are at the heart of the integration between survival and
noxious signals; therefore, modulation of the mitochondrial functions carried out by GSK-3
is profoundly involved in the apoptosis escape capabilities that hallmark neoplasms. This
review brieﬂy covers the mechanistic interactions among oncogenic kinase pathways,
GSK-3 activity and subsequent modulation of mitochondrial functions that shape the
pro-survival phenotype of cancer cells, such as control of redox homeostasis and inhibition
of the mitochondrial permeability transition pore.
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INTRODUCTION
GSK-3 is a Ser/Thr protein kinase ubiquitously expressed and
extremely conserved in all cell types of every eukaryotic species
examined to date. There are two GSK-3 isoforms, GSK-3α and
GSK-3β, which are highly homologous and have been implicated
in a variety of critical regulatory roles. Little is known about the
respective functional roles of the two kinase isoforms, and GSK-
3α andGSK-3β are largely interchangeable (Juhaszova et al., 2009).
Thus, for the sake of simplicity, we will discuss about GSK-3 func-
tions without discriminating between the two isoenzymes, even if
most studies of GSK-3 and mitochondria refer to GSK-3β.
At variance from the majority of kinases, GSK-3 is constitu-
tively active, and more than 50 substrates have been identiﬁed.
Dysregulation of GSK-3 is linked to a large number of preva-
lent diseases including psychiatric disorders, neurodegenerative
diseases, ischemia/reperfusion injury, diabetes, and cancer (Jope
and Johnson, 2004; Miura et al., 2010; Medina et al., 2011). In the
present review we will analyze the role played by GSK-3 in tumor
cells, with a particular focus on biological processes involving
mitochondria.
GSK-3 REGULATION
GSK-3 activity is regulated in several ways: by inhibitory phospho-
rylation at aN-terminal Ser residue; by activating phosphorylation
on a Tyr residue; following priming phosphorylation of substrates
by other kinases; by subcellular localization and by binding to
scaffold proteins in multimeric complexes (Jope et al., 2007). Ser
phosphorylation within its N-terminal region (at Ser9 of GSK-3β
or Ser21 of GSK-3α) is a major mechanism for inhibiting GSK-
3 enzymatic activity (Figure 1), as it creates a “pseudosubstrate”
which intramolecularly binds to a phosphoprotein binding pocket
within the active site of the kinase, suppressing activity by occlud-
ing primed substrate access to the pocket (Woodgett and Cohen,
1984; Frame et al., 2001). Multiple transduction pathways that are
constitutively activated in tumors converge on GSK-3 to induce
phosphorylation at Ser9/21 residues. GSK-3 activity is inhibited
by growth factor signaling either through the PI3Kpathway (Stam-
bolic and Woodgett, 1994; Shaw and Cohen, 1999) or the MAPK
cascade (Saito et al., 1994; Brady et al., 1998); and in response to
agonists that activate the protein kinase A (PKA) (Fang et al., 2000;
Li et al., 2000) or the protein kinase C (PKC) (Ballou et al., 2001;
Fang et al., 2002). All these signals contribute to the oncogenic
process by removing the tonic inhibitory effect exerted by GSK-3
on a plethora of biochemical cascades. The phosphorylation state
of these Ser residues is dynamic, as the effect of the kinases is
counterbalanced by GSK-3 dephosphorylation mediated by pro-
tein phosphatase-1 (Zhang et al., 2003). This process is further
modulated, as GSK-3 Ser9/21 phosphorylation is facilitated when
the Thr43 and Ser389/Thr390 residues in GSK-3β are phospho-
rylated by ERK- and p38-MAPK, respectively. Conversely, GSK-3
enzymatic activity is maximal following phosphorylation on Tyr-
216 or Tyr-279 of GSK-3β and GSK-3α, respectively. These Tyr
residues are autophosphorylated (Lochhead et al., 2006), although
thepossibility that other tyrosine kinases are responsible forGSK-3
tyrosine phosphorylation cannot be ruled out (Cole et al., 2004).
Substrate speciﬁcity is inﬂuenced both by GSK-3 distribution
in cell compartments (i.e., cytoplasm, nucleus, or mitochondria),
and by its tendency to associate with other proteins in multi-
meric functional complexes. This is particularly important, as
GSK-3 targets substrates that have already been primed, i.e., phos-
phorylated by another kinase present in the complex; the ideal
phosphoacceptor site for GSK-3 is a Ser or Thr located four
residues upstream to an already phosphorylated hydroxyamino
acid (Woodgett and Cohen, 1984). An example is provided by
the large molecular machinery that comprises Axin, adenopatous
polypolis coli (APC), caseine kinase 1 (CK1), β-catenin, and GSK-
3, which is engaged by the canonical Wnt signaling pathway and
whose dysregulation is causative of diverse tumor types (Polakis,
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FIGURE 1 | GSK-3 modulates mitochondrial PTP opening downstream to
kinase signaling activated during neoplastic transformation.The active
form of GSK-3 phosphorylates both Bax and VDAC: Bax is activated and
migrates to the outer mitochondrial membrane (OMM), where it oligomerizes
and induces membrane permeability; phosphorylated VDAC becomes a
consensus site for Bax which displaces HK II from the same binding site. The
mitochondrial fraction of GSK-3 can facilitate PTP opening by CyP-D
phosphorylation. Ser phosphorylation of both cytoplasmic and mitochondrial
GSK-3 by several kinases, such as AKT and ERK, critically contributes to
defuse the mitochondrial apoptotic machinery downstream to ligand- or
oncogenically activated receptor tyrosine kinases. GSK-3 inhibitory
phosphorylation in enhanced by regulatory loops that involve ERK and p38
MAPK targeting other Ser andThr residues on GSK-3. PTP inhibition is elicited
both by dephosphorylated VDAC, which has high afﬁnity for HK II and
competitively displaces Bax from the OMM, and by active mitochondrial ERK,
which inhibits mGSK-3 by Ser phosphorylation, in turn blocking CyP-D
phosphorylation and PTP induction. Contextually, the absence of
GSK-3-dependent Bax activation inhibits Bax relocation in the OMM.
2007). In this complex, co-localization of GSK-3 with a speciﬁc
subset of binding proteins favors selective protein:protein inter-
actions, leading to CK1-dependent priming of β-catenin, which
is subsequently phosphorylated by GSK-3 and tagged for protea-
somal degradation, thus blocking its transcription activity that
favors cell proliferation (Wu and Pan, 2010).
GSK-3 AND Bcl-2 FAMILY PROTEINS
GSK-3 contributes to the anti-apoptotic phenotype of cancer
cells by controlling the mitochondrial localization and the acti-
vation status of a number of proteins of the cell death machinery,
shaping the ability of cell death escape that hallmarks malignan-
cies. Numerous proteins relevant to cell death [i.e., Mcl-1, Bcl-2,
Bax, Noxa, voltage-dependent anion channel (VDAC), and ade-
nine nucleotide transporter (ANT)] are board of GSK-3 and are
located or can translocate in mitochondria. As a general rule,
intrinsic apoptosis elicited by a variety of stress conditions that
can be encountered by a malignant cell, such as withdrawal of
growth factors, chemotherapeutics, or oxidant stress, is facili-
tated by active GSK-3 (Beurel and Jope, 2006). Thus, GSK-3
activity potentially counteracts neoplastic transformation. The
phosphorylation of targets located on the external surface of mito-
chondria does not strictly require a mitochondrial localization of
GSK-3, but it is plausible to envisage that the enzyme must be
associated to outer membrane components. GSK-3 regulates sev-
eral members of the B-cell lynphoma-2 (Bcl-2) protein family: it
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prompts phosphorylation-mediated proteasomal degradation of
the anti-apoptotic protein myeloid cell leukemia-2 (Mcl-2) (Mau-
rer et al., 2006; Ding et al., 2007a),whose expression correlateswith
Ser-phosphorylation dependent inactivation of GSK-3 in diverse
cancer cell types (Ding et al., 2007b), whereas a decreased phos-
phorylation of potential GSK-3 target sequences on Bcl-2 itself
contributes to its anti-apoptotic activation (Juhaszova et al., 2009).
GSK-3 inhibition abolishes both the mitochondrial translocation
and the conformational activation of the pro-apoptotic protein
Bcl-2 associated X (Bax) through direct phosphorylation of a Ser
residue on Bax found within a putative GSK-3 phosphorylation
motif; and a constitutively active GSK-3 prompts Bax localiza-
tion to mitochondria (Linseman et al., 2004; Ohori et al., 2008;
Ge et al., 2012; Ngok-Ngam et al., 2013). In contrast with these
observations, it was shown in human colorectal cancer cells that
pharmacologic inhibition of GSK-3 elicited p53-dependent con-
formational activation of Bax, resulting in apoptosis induction
(Tan et al., 2005). Moreover, treatment of melanoma cells with
the multiple kinase inhibitor sorafenib activates GSK-3, leading
to down-modulation of the pro-apoptotic Bcl-2 family mem-
ber Noxa (Panka et al., 2008). These ﬁndings suggest that, at
least in some neoplastic models, GSK-3 inhibition could enhance
apoptosis.
GSK-3 AND HEXOKINASE II
GSK-3 also regulates tumor cell survival by controlling mitochon-
drial binding of hexokinase, particularly hexokinase type II (HK
II), which is highly expressed on the outer mitochondrial mem-
brane (OMM) of most cancer cells. HK initiates the process of
intracellular glucose utilization and it contributes to the War-
burg effect, i.e., to the uncoupling between glycolysis enhancement
and oxygen availability (Warburg, 1956; Hsu and Sabatini, 2008),
supporting cell proliferation in the hypoxic conditions of pri-
mary tumor mass accrual. Association of HK II to the OMM is
enhanced when GSK-3 is inactivated through phosphorylation by
the survival kinase Akt, whose signaling is constitutively induced
in most tumor types. Accordingly, activation of GSK-3 was shown
to induce the release of HK II from the OMM (Mathupala et al.,
2006; Robey and Hay, 2006). It was found that release of HK
II from mitochondria induces apoptosis in hepatocellular carci-
noma cells (Kim et al., 2007), and in glioma cells (Machida et al.,
2006). We have observed both in tumor cell models and in car-
diomyocytes that detachment of HK II from mitochondria by a
selective peptide elicits opening of the inner membrane channel
permeability transition pore (PTP), which irreversibly commits
cells to death (Chiara et al., 2008). Thus, kinase cascades aber-
rantly boosted in neoplasms such as the PI-3K/Akt pathway funnel
signals that inhibit GSK-3 and keep HK II bound to the mito-
chondrial surface, which maintains the PTP locked contributing
to the anti-apoptotic phenotype of tumor cells; whereas GSK-3
activation lowers the threshold for cell death induction by favor-
ing mitochondrial detachment of HK II and the ensuing PTP
opening. The mechanism by which GSK-3 controls the mito-
chondrial localization of HK II remains unclear. It was proposed
that GSK-3 phosphorylation of the VDAC on the OMM could
induce cell death favoring the interaction between VDAC and
the pro-apoptotic Bax/Bcl-2 homologous antagonist killer (Bak)
proteins in conditions of nutrient starvation (Mathupala et al.,
2006; Robey and Hay, 2006). However, the physiological role
of GSK-3-mediated phosphorylation of VDAC is unknown, as
mitochondrial displacement of HK II elicits cell death also in con-
ditions of GSK-3 inhibition, in cells lacking any detectable binding
between HK II andVDAC (Chiara et al., 2008), and in the absence
of Bax and Bak (Majewski et al., 2004). Moreover, after Ser phos-
phorylation GSK-3 interacts with the mitochondrial ANT but not
with VDAC (Nishihara et al., 2007), and this binding could play a
role in protection from oxidative insults leading to PTP opening,
at least in cardiomyocyte models.
THE MITOCHONDRIAL POOL OF GSK-3
After the ﬁrst detection of GSK-3 in mitochondria of rat cere-
bellum (Hoshi et al., 1995), a number of observations have clearly
established that a fraction of the enzyme localizes inmitochondria.
Mitochondrial GSK-3 (mGSK-3) contributes to the regulation
of energy metabolism: it down-modulates both the Krebs cycle,
by inactivating pyruvate dehydrogenase (Hoshi et al., 1996), and
oxidative phosphorylation, by inhibiting NADH:ubiquinone oxi-
doreductase, i.e., respiratory chain (RC) complex I (King et al.,
2008). As RC complexes are the main site of reactive oxygen
species (ROS) production in the cell (Murphy, 2009), mGSK-3
is involved in the homeostatic redox equilibrium, whose dysregu-
lation can lead to a number of pathological conditions. mGSK-3
inhibition activates an anti-oxidant response that reduces damage
and promotes mitochondrial biogenesis during ischemic cerebral
injury (Valerio et al., 2011), whereas it prevents ROS-dependent
PTP opening in a model of hepatic ischemia/reperfusion (Varela
et al., 2010). Tumour necrosis factor-alpha (TNF-α), whose
signaling is constitutively enhanced during chronic liver inﬂam-
mation, induces a ROS-dependent activation of mGSK-3 that
causes depletion of mitochondrial DNA in human hepatic cells
(Vadrot et al., 2012). mGSK-3 is the point of convergence of sev-
eral transduction pathways that regulate PTP opening following
ischemia/reperfusion in the heart (Juhaszova et al., 2004), includ-
ing the survival kinases Akt and Erk1/2, PKCε, protein kinase
G (PKG) and p70s6K (Hausenloy and Yellon, 2007); notably,
effectiveness of ischemic pre- and post-conditioning in preserv-
ing cardiomyocyte viability requires mGSK-3 inhibition through
Ser phosphorylation, which in turn inhibits the PTP in response
to ROS or Ca2+ overload (Juhaszova et al., 2009; Miura and
Miki, 2009; Miura et al., 2010). Accordingly, a signiﬁcant increase
in active, Ser-dephosphorylated mGSK-3 is observed during
ischemia (Miura and Tanno, 2012).
The molecular mechanisms that regulate the mitochondrial
pool of GSK-3 and in turn the PTP in cardiomyocytes could be rel-
evant toneoplasms too, strongly contributing to the anti-apoptotic
phenotype of tumor cells. Indeed, several data indicate that PTP
dysregulation has a role in tumorigenesis, increasing resistance of
neoplastic cells to a variety of stressful conditions such as exposure
to chemotherapeutics, hypoxia, or detachment from the extracel-
lular matrix (Rasola et al., 2010b). Even if the lack of a molecular
characterization of the PTP hampers a thorough characterization
of itsmodulation bymGSK-3, it is conceivable thatmGSK-3 could
contribute to PTP regulation both by acting as a downstreameffec-
tor of diverse signaling pathways, and by changing mitochondrial
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ROS levels, as ROS are well-established PTP inducers (Rasola and
Bernardi, 2011). Tumor cells are particularly exposed to the nox-
ious effects of loss of redox homeostasis, as they are endowed
with abnormally high ROS levels (Cairns et al., 2011). Thus, by
modulating the PTP mGSK-3 could crucially affect the survival
potential of neoplastic cells. Accordingly, it was observed that
mGSK-3 activation enhances ROS production and apoptosis fol-
lowing treatment of neurons and of human neuroblastoma cells
with complex I inhibitors (King et al., 2008; Petit-Paitel et al.,
2009). Moreover, we and others have observed that cyclophilin
D (CyP-D), a mitochondrial chaperone that regulates the PTP
(Rasola and Bernardi, 2007), is directly phosphorylated by GSK-
3 on Ser/Thr residues in tumor cell models (Rasola et al., 2010a;
Traba et al., 2011) or in cells lackingmitochondrial DNA and char-
acterized by a Warburg-like metabolic phenotype (Masgras et al.,
2012). We found that a portion of ERK locates in the mitochon-
drial matrix, and mitochondrial ERK, which turned out to be
constitutively active after v-Ki-Ras dependent transformation or
in diverse neoplastic cell types, inhibits mGSK-3 by Ser phos-
phorylation, thus conferring resistance to death stimuli acting as
PTP inducers (Rasola et al., 2010a). Moreover, ERK inhibition
increasedGSK-3-dependent phosphorylation of CyP-D and sensi-
tization of PTP to opening, thus signiﬁcantly abolishing tumor cell
protection from apoptosis, whereas pharmacological inhibition of
GSK-3 protected from PTP opening (Rasola et al., 2010a).
GSK-3, MITOCHONDRIA AND CHEMOTHERAPY
GSK-3 displays amultiplicity of functions in distinct cellular com-
partments and in a variety of cell types, and it is involved in several
disorders. This makes GSK-3 an interesting target for drug discov-
ery, but at the same time considering GSK-3 as a therapeutic target
exposes to the risk of undesired side effects, particularly when
patients are treated in a chronic mode. During the last decade, a
priority has been given to the search for GSK-3 inhibitors, and
promising data exist for the treatment of neurological disorders
and diabetes (Gould et al., 2006; Gao et al., 2011). In the ﬁeld of
cancer chemotherapy, GSK-3 mainly acts as a tumor suppressor
by inhibiting many proto-oncogenic proteins and tumor develop-
ment. Nonetheless, in neoplasms such as human ovarian, colon,
hepatic andpancreatic carcinomas, some studies suggest thatGSK-
3 may actually exert a pro-neoplastic function, and inactivation of
GSK-3 is associated with growth suppression of medullary thyroid
cancer cells (Luo, 2009). As a consequence, targeting GSK-3 with
drugs that could act as anti-neoplastic agents is an extremely com-
plicated issue. For instance, GSK-3 displays a tumor suppressor
activity in mammary tumors, and its activation causes sensiti-
zation to chemotherapeutics of breast cancer cells, but in colon
cancer, where the enzyme is a tumor promoter, GSK-3 must be
inhibited to increases the effect of chemotherapy (Luo, 2009).
These paradoxical observations are probably explainable by the
pleiotropy of GSK-3 functions, and a better comprehension of
FIGURE 2 | Molecular mechanisms elicited by the recently
synthesized gold-compoundAUL12 to specifically induce cell
death of tumor cells. AUL12 inhibits the complex I of the mitochondrial
respiratory chain thus eliciting an increase in ROS levels. The ROS surge
reactivates the oncogenically inhibited GSK-3; mitochondrial GSK-3
phosphorylates CyP-D, unlocking the PTP blocked by oncogene
signaling; cytosolic GSK-3 binds to and phosphorylates Bax,
leading to its mitochondrial translocation. Mitochondrial Bax
prompts mitochondrial permeabilization at least partially by inducing
the PTP.
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its molecular targets in the different subcellular locations could
help to reﬁne pharmacological approaches. The key role played
by mitochondria in cell death regulation makes the mitochondrial
function of GSK-3 a particularly attractive area of investigation.
As an example, in hepatoma cells the effect of chemotherapy
can be enhanced by pharmacological inhibition of the PI-3K
signaling pathway, as this reactivates GSK-3 and facilitates mito-
chondrial translocation of Bax and the ensuing apoptosis (Beurel
et al., 2005).
In this conceptual framework, we have recently characterized
the mitochondrial effects of the Gold(III)-dithiocarbamato com-
plex AUL12, a gold-based chemotherapeutic of new generation
designed with the speciﬁc aim of improving selectivity, bioavail-
ability, and efﬁcacy of platinum-based compounds, diminishing
their toxic side effects (Ronconi and Fregona, 2009). It was
observed that AUL12 increases intracellular ROS levels (Saggioro
et al., 2007); therefore, our idea was to target the increased ROS
levels that characterize tumor cells. As cancer cells are forced to
induce anti-oxidant defenses to set a novel homeostatic redox
equilibrium, we reasoned that a further increase in ROS levels
could overwhelm their residual anti-oxidant capabilities, trigger-
ing PTP opening and cell death in a selective way, i.e., without
a major damage to non-transformed cells. We observed (Chiara
et al., 2012) that AUL12 elicits a rapid burst of mitochondrial
superoxide levels following inhibition of the RC complex I, which
causesGSK-3Tyr-phosphorylation and activation. Themitochon-
drial fraction of GSK-3 phosphorylates CyP-D, which in turn
facilitates PTP opening, whereas the cytosolic GSK-3 interacts
with Bax and prompts its mitochondrial translocation, where it
contributes to PTP induction and tumor cell death (Figure 2).
Notably, AUL12 was much less toxic on non-transformed cells
and after in vivo administration (Marzano et al., 2011).
These ﬁndings provide evidence that targeting speciﬁc signal-
ing pathways maintained by mitochondria in tumor cells allow to
shut crucial mechanisms that shield neoplasms from the toxicity
of many anti-neoplastic strategies, and pave the way for the design
of a new family of chemotherapeutic compounds that sensitize
cancer cells to chemotherapy.
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